Literature DB >> 11122835

Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia.

M L Heaney1, D W Golde.   

Abstract

The separation of myelodysplastic syndromes from acute myeloid leukemia has been problematic because, as clinical entities, they represent different points in the spectrum of the same disease process. A new classification by the World Health Organization has incorporated recent prognostic findings in myelodysplastic syndrome and distinct genetic subtypes of acute myelogenous leukemia to provide an improved conceptual framework, if not a simpler nomenclature. Here, we review the new classification system and discuss its impact on diagnosis and treatment.

Entities:  

Mesh:

Year:  2000        PMID: 11122835     DOI: 10.1007/s11912-000-0085-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  15 in total

Review 1.  Myelodysplasia.

Authors:  M L Heaney; D W Golde
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

Review 2.  The 5q- abnormality.

Authors:  S D Nimer; D W Golde
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

3.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

4.  Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.

Authors:  E Estey; P Thall; M Beran; H Kantarjian; S Pierce; M Keating
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

Review 5.  The 5q-syndrome.

Authors:  J Boultwood; S Lewis; J S Wainscoat
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

6.  Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).

Authors:  T de Witte; S Suciu; M Peetermans; P Fenaux; P Strijckmans; M Hayat; B Jaksic; D Selleslag; R Zittoun; M Dardenne
Journal:  Leukemia       Date:  1995-11       Impact factor: 11.528

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

Review 8.  Classification of acute leukemia.

Authors: 
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

9.  Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.

Authors:  R S Stein; R I Abels; S B Krantz
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

10.  Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.

Authors:  E Hellström-Lindberg
Journal:  Br J Haematol       Date:  1995-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.